Navigation Links
Akela Pharma initiates its first abuse deterrent opioid Phase I clinical trial
Date:3/6/2008

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, March 6 /PRNewswire-FirstCall/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it has started its first EDACS(TM) product Phase I clinical trial. EDACS(TM) is Akela's patent pending platform technology to prevent abuse of controlled substances.

This Phase I trial for the first EDACS(TM) based product is an open-label, randomized, single-dose, cross-over study investigating the pharmacokinetics and safety of 3 different extended release formulations of a well-known opioid product compared to the same opioid drug immediate release formulation. The study will be carried out in 12 healthy subjects, and the results are expected to be available in Q3/2008.

"The abuse of prescription drugs is approaching epidemic proportions in numerous countries. The costs to society associated with this abuse are tremendous. Akela has developed a platform technology to prevent the abuse of such substances by preventing the tampering of extended release dosage forms as well as unintentional dose dumping in alcohol. " said Dr. Halvor Jaeger, Chief Executive Officer of Akela Pharma Inc. "We believe that our platform technology is perfectly suited to meet the increasing market demand as well as regulatory pressure for abuse deterrent formulations."

About EDACS(TM):

EDACS(TM) is a patent pending platform technology which utilizes extrusion technology to prepare an insoluble matrix containing dispersed drug which can be shaped into tablets. The matrix is water insoluble, slightly soluble in ethanol, not friable, does not break on compression or allow for crushing and inhalation and does not allow for dissolution and injection.

About Akela Pharma Inc.:

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation and pain markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 11.7 million shares outstanding.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of Akela Pharma Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


'/>"/>
SOURCE Akela Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
2. Akela Pharma provides corporate update
3. Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial
4. Akela Pharma reports results for third quarter of fiscal 2007
5. AKELA Pharma Inc. announces U.S. public offering and proposed listing
6. Akela Pharma Inc. Completes Share Consolidation
7. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
8. MinuteClinic Hits 500th Clinic Mark; New Locations Open in Dallas, Los Angeles and Orlando CVS/pharmacy Stores
9. Notice of Bradmer Pharmaceuticals Conference Call
10. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
11. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... 28, 2016 , ... ProText Layouts is a set of 30 self-animating kinetic ... With ProText Layouts, video editors can create an energetic typography video with incredible ease. ... texts. Creating text-based videos have never been easier. , ProText Layouts includes 30 ...
(Date:4/28/2016)... ... April 28, 2016 , ... CastCoverz!, America’s ... with AquaShieldUSA, the country's oldest waterproof cast protector . As the largest ... the largest selection of daily, night, weatherproof and waterproof covers for most orthopedic ...
(Date:4/28/2016)... ... ... University of New England President Danielle N. Ripich is pleased to announce ... In addition to his role as director of Athletics, McDonald will oversee a ... space of just one year Jack has distinguished himself by his commitment to our ...
(Date:4/28/2016)... ... April 28, 2016 , ... The ARRS ... events, attracting medical professionals from around the globe who attended a week’s worth ... Ceremonies Sunday, April 17 included the introduction of the 2016 ARRS Distinguished Educator, ...
(Date:4/28/2016)... ... April 28, 2016 , ... Trinity Health, ... Kids, a leading force in the fight to reduce tobacco use and its ... that can help reduce tobacco use. The initiative brings together two organizations committed ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... TOKYO , April 28, 2016 ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for ... and Pharmacovigilance team to bring a wealth of insight to a ... unparalleled pharmacovigilance knowledge. George Phillips joined ArisGlobal ...
(Date:4/28/2016)... 28, 2016 New market ... is a report that provides an overview of ... pipelines by identifying new targets and MOAs to ... Profiles discussed in this H1 2016 Osteoarthritis Pipeline ... AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios ...
(Date:4/27/2016)... April 27, 2016 Elekta today ... platform will be the focal point of seven scientific ... European Society for Radiotherapy & Oncology, taking place April ... a state-of-the-art radiotherapy system and a high-field MRI scanner ... see the patient,s anatomy in real time. The MR-linac ...
Breaking Medicine Technology: